XF-73

XF-73

Identifiers
CAS Number	718638-68-7
3D model (Jmol)	Interactive image
ChemSpider	8094227
PubChem	9918582
InChI InChI=1S/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;; Key: BXHQXSXRVAELBC-XRFOENPRSA-L InChI=1/C44H50N6O2.2ClH/c1-49(2,3)25-7-27-51-37-17-9-31(10-18-37)43-39-21-13-33(45-39)29-35-15-23-41(47-35)44(42-24-16-36(48-42)30-34-14-22-40(43)46-34)32-11-19-38(20-12-32)52-28-8-26-50(4,5)6;;/h9-24,29-30,45-46H,7-8,25-28H2,1-6H3;2*1H/q+2;;/p-2/b33-29-,34-30-,35-29-,36-30-,43-39-,43-40-,44-41-,44-42-;; Key: BXHQXSXRVAELBC-NDLTUMITBE
SMILES C[N+](C)(C)CCCOC(C=C1)=CC=C1/C(C2=CC=C(/C=C3C=CC(/C(C4=CC=C(OCCC[N+](C)(C)C)C=C4)=C(N/5)/C=CC5=C\6)=N/3)N2)=C7N=C6C=C/7.[Cl-].[Cl-]
Properties
Chemical formula	C44H50Cl2N6O2
Molar mass	765.82 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial that works via weakening bacteria cell walls.^[1] It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.^[2][3][4]

Structurally it is a dicationic porphyrin.^[5]

It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.^[1][6]

In 2014 a phase 1 clinical trial for nasal administration was run.^[7]

As of February 2016 another phase 1 clinical trial (for nasal administration) is recruiting.^[8]

References

1. Neka Sehgal (20 September 2010). "Promising new drug XF-73 kills superbugs within 5 minutes". Archived from the original on 21 July 2011.
2. "XF-73". Destiny Pharma. (Shows molecular structure.)
3. Miller, K.; Ooi, N.; Hobbs, J. K.; Rhys-Williams, W.; Love, W. G.; Hayter, I.; Katila, M.; Chopra, I. (19 April 2008). "XF-73, a novel anti-staphylococcal antimicrobial with very rapid bactericidal activity". European Society of Clinical Microbiology and Infectious Diseases.
4. Mary Dejevsky (18 May 2008). "Scientists 'on brink of cure' for superbug". The Independent.
5. "XF series". Destiny Pharma.
6. Tom Chivers (18 May 2008). "MRSA: UK scientists 'close to a treatment". The Daily Telegraph.
7. Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
8. Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73